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Introduction

Methods
110
Search strategy
111
We searched all studies published up to November 11, 2018 from the following databases:
112
Embase, PubMed, Web of Science and the Cochrane library. Search terms used were: 113 "Mycobacterium tuberculosis", "tuberculosis", "tuberculous meningitis", "meningitis",
114
"cerebrospinal fluid", "CSF", "molecular diagnostic techniques", "nucleic acid amplification",
115
"diagnosis", "Polymerase Chain Reaction", "PCR", "loop mediated isothermal amplification",
116
"LAMP", "GeneXpert", "Xpert", "ligase chain reaction", "LCx", "Amplicor", "ProbeTec",
117
"Gen-probe", "GenoType MTBDR", "Cobas", "Roche", "Abbott" and "Cepheid". In addition,
118
we searched references of included articles to find relevant studies. Only studies written in
The studies found through databases that were duplicates were removed using EndNote X7
123
(Thomson Reuters, New York, NY, USA). Records were initially screened by title and abstract 124 by two independent reviewers (AP, MJN) to exclude those not related to the current study. The 125 full-text of potentially eligible records was retrieved and examined. Any discrepancies were 126 resolved by consensus.
127
Inclusion criteria
128
Studies were included if they report a comparison of an NAA test against a reference standard 129 and provide data necessary for the computation of both sensitivity and specificity. We used the 
136
Exclusion criteria
137
Studies were excluded if they: did not report confirmed and/or suspected TBM based on
138
Thwaites and Marais diagnostic criteria, did not report sufficient data for computation of 139 sensitivity and specificity and did not contain enough samples (≤10 CSF samples).
140
Data extraction
141
The following items were extracted from each article: first author, year of publication, study 142 time, study location, type of NAA test used, reference standard used, number of confirmed TBM 143 cases, number of suspected TBM cases and number of non-TBM (controls). Two reviewers (AP 144 and MJN) independently extracted data and differences were resolved by consensus.
145
Quality assessment
146
The methodological quality of the studies was assessed using the QUADAS-2 checklist (26). 
152
The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence 153 intervals between NAA tests and reference standard were assessed. A random effects model was 154 used to pool the estimated effects. Diagnostic accuracy measures [i.e. the summary receiver 155 operating characteristic (SROC) curve, the summary positive likelihood ratios (PLR), negative 156 likelihood ratios (NLR) and DOR] were calculated. A value of pooled PLR greater than 10 and 157 of pooled NLR less than 0.1 were noted as providing convincing diagnostic evidence (27, 28) .
158
The heterogeneity among the studies was assessed using Chi-square test and I-square statistics.
159
To identify the risk of publication bias, Deek's test was used, based on parametric linear 160 regression methods (29). Subgroup analysis was conducted using several study characteristics 161 separately.
162
Results
163
Figure 1 summarizes the study selection process. Briefly, we retrieved data from 63 selected 164 articles comprising 1381 confirmed TBM cases and 5712 non-TBM controls. These 63 studies 165 were divided into two groups comprising 71 datasets (43 in-house tests and 28 commercial tests) 166 that used culture as the reference standard and 24 datasets (21 in-house tests and 3 commercial 167 tests) that used a CRS. Characteristics of the included studies are described in Table 1 . The 168 studies were conducted in 22 different countries: India was the most frequently represented 169 country (28 out of 63, 44.4%).
170
Risk of bias assessment
171
Based on the QUDAS-2 tool, all included records were identified as having a low risk of bias, 172 thereby increasing the strength of scientific evidence of the current study (Figure 2 ). The quality 173 assessment for each included study is provided in Figure S1 .
174
Overall diagnostic accuracy of NAA tests against culture 175 The overall pooled estimates of sensitivity, specificity, PLR, NLR and DOR of NAA tests 176 against culture were 82% (95% CI: 75-87), 99% (95% CI: 98-99), 58.6 (35.3-97. 3), 0.19 (0.14- The pooled sensitivity and specificity estimates of in-house NAA tests against culture were 87%
183
(80-92) and 99% (97-99). The PLR, NLR, DOR and AUC estimates were found to be 64.6 (28.4-184 147.0), 0.13 (0.08-0.20), 372 (165-839) and 98% (97-99), respectively (Table 2, Figure S2 , S3).
185
Diagnostic accuracy of commercial tests against culture
186
The pooled sensitivity and specificity estimates of commercial tests against culture were 67% Figure S4 , S5).
190
Overall diagnostic accuracy of NAA tests against CRS
191
The overall pooled estimates of sensitivity, specificity, PLR, NLR, DOR and AUC of NAA tests of publication bias (Deek's Test P value was 0.01).
195
Diagnostic accuracy of in-house tests against CRS
196
The pooled sensitivity of in-house NAA tests against CRS was 68% (38-88), and the pooled 197 specificity was 98% (95-1.00) (Table 2, Figure S6 , S7). The PLR, NLR, DOR and AUC 198 estimates were 44.4 (16.0-123.2), 0.32 (0.14-0.75), 138 (41-468) and 98% (96-99) , respectively.
199
Diagnostic accuracy of commercial tests against CRS
200
The pooled sensitivity of commercial NAA tests against CRS was 53% (33.4-73.4) , and the analysis of the use of the GeneXpert MTB/RIF assay has been completed and suggests that this 258 technology is likely to be a highly cost-effective method of TB diagnosis; however, these 259 analyses were not TBM specific (33-36).
260
More recently, Bahr et al evaluated the diagnostic performance of the new GeneXpert MTB/RIF 261 Ultra (Xpert Ultra) for TBM (23). They found Xpert Ultra had 95% sensitivity for TBM 262 compared to a CRS of any microbiologic test being positive. When Xpert Ultra was excluded 263 from the reference standard, sensitivity was 70%. In both analyses, Xpert Ultra's sensitivity was 264 higher than either Xpert or culture, leading the WHO to recommend Xpert Ultra as the initial test 265 for TBM (23, 32, 37) .
Some limitations of this study should be taken into consideration. First, heterogeneity exists 267 among the included studies. To explore the heterogeneity of studies, we conducted subgroup, 268 meta-regression and sensitivity analyses. The subgroup and meta-regression analyses found that 269 variables such as NAA techniques and standard tests could be probable reasons of heterogeneity.
270
Second, we could not address the effect of factors such as sample volume, processing steps, 271 amplification protocols, expertise with NAA tests and laboratory infrastructure on the accuracy of NAA 272 tests due to a high level of variability in these factors and/or reporting of these factors in the studies. 273
Finally, as with any systematic review, limitations associated with potential publication bias 274 should be considered.
275
Conclusions
276
The analysis has demonstrated that the diagnostic accuracy of NAA tests is currently insufficient The SROC plot shows summary of test performance, visual assessment of threshold effect, and 588 heterogeneity of data in ROC space between sensitivity and specificity; each circle in the SROC 589 plot represents a single study, summary operating sensitivity specificity, and SROC curve with 
